association between the pro12ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and inflammatory bowel disease a meta-analysis协会pro12ala多态性之间的过氧物酶体proliferator-activated受体γ2和炎症性肠病一个荟萃分析.pdf

Association between the Pro12Ala Polymorphism of Peroxisome Proliferator-Activated Receptor Gamma 2 and Inflammatory Bowel Disease: A Meta-Analysis 1 . 2. 1 1 1 Zhi-Feng Zhang * , Ning Yang , Gang Zhao , Lei Zhu , Li-Xia Wang 1 Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, Dalian, China, 2 Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian, China Abstract Background: Peroxisome proliferator-activated receptor gamma (PPARc), a nuclear receptor, has been implicated playing a role in the development of inflammatory bowel disease (IBD). However, previous studies evaluating the association between the PPARc2 Pro12Ala polymorphism and IBD are inconsistent. We performed a meta-analysis to determine whether the PPARc2 Pro12Ala mutation was associated with the presence of IBD. Methods and Findings: Electronic databases were searched for case-control studies evaluating the association between the Pro12Ala mutation and the presence of IBD. Effects were summarized with the methods recommended by the Cochrane ` Collaboration. A total of 7 studies including 1002 ulcerative colitis (UC) cases, 1090 Crohns disease (CD) cases and 1983 controls were involved in this meta-analysis. In the overall analysis, no significant association of this polymorphism with UC or CD was found. In the subgroup analyses in different populations, AlaAla genotype seemed to protect the European Caucasian population against the development of CD (Pro vs Ala: OR = 1.135, 95%CI = 0.951–1.354, P = 0.162, Bon = 1.000; ProPro vs ProAla: OR = 1.042,